Heat Biologics is a biopharmaceutical company developing immunotherapies focused on activating a patient's immune system against cancer through T-cell activation and expansion. Co.'s T-cell Activation Platform, includes two variations for intradermal administration, Immune Pan-antigen Cytotoxic Therapy and Combination Pan-antigen Cytotoxic Therapy. To further augment antigen experienced T-cell activation and expansion, Co. is also developing a T-cell co-stimulator PTX-35 for systemic administration. These programs are designed to harness the body's natural antigen specific immune activation and tolerance mechanisms to reprogram immunity and provide a long-term clinical effect. The HTBX stock yearly return is shown above.
The yearly return on the HTBX stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2016 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the HTBX annual return calculation with any dividends reinvested as applicable (on ex-dates).
|